RS-2022-00167083

Investigation of proper candidates for in vivo direct lineage reprogramming based SCI gene therapy development

Stand Up Therapeutics

NEUROSCIENCE	Candidate

Product Type	Gene therapy
Indication	Spinal cord injury
Target	Astrocytes
MoA(Mechanism of Action)	Cell fate conversion of astrocytes into induced motor neurons
Competitiveness	• In general, stem cell therapy takes a long period and high cost • AAV-based therapy can be treated with a single dose • Applicable to patients with chronic spinal cord injury • Effects continue for a long period due to the production of motor neurons
Development Stage	Candidate
Route of Administration	Intraparenchymal injection

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund